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Orbital Embryonal Rhabdomyosarcoma in Karachi (1998-2002)
Y. Bhurgri1,2,3, A. Mazhar1, H. Bhurgri1,2, A. Usman4, J. Malik5, A. Bhurgri1,3, R. Ahmed2, S. Muzaffar2, N. Kayani2, S.
Pervez2, S. H. Hasan2
Karachi Cancer Registry1, Department of Pathology, Aga Khan University Hospital2, Department of Pathology, Sindh Medical College3, Jinnah
Postgraduate Medical Centre4, Ziauddin Cancer Hospital5, Karachi.
Abstract
Objective: To study the epidemiology of ocular Rhabdomyosarcoma (ORMS) in Karachi.
Methods: Incident ORMS cases resident of Karachi, registered at Karachi Cancer Registry (KCR) during 1st
January 1998 to 31st December 2002 were included in the study. The data were classified using ICD-O2; com-
puterized with Canreg-3, and analyzed using SPSS 10.0.   
Results: Ten cases of ORMS were reported to KCR during 1998-2002. RMS originated in the orbit in eight
cases, conjunctiva in one and eyelid in one. Nine cases presented with proptosis, associated with conjunctivitis
in four cases. One case presented with eyelid swelling. The crude annual incidence rate was 0.13/100,000, the
age standardized rate was 0.3/100,000. The mean age of childhood cases was 10.4 years (95% CI 4.0; 16.7);
and adult cases was 24.8 years (95% CI 12.8; 36.7). At presentation, eight patients were older than 10 years
and three were older than 20 years. Five cases were categorized as childhood malignancies. Tumors were a
TNM stage III disease at presentation in eight cases; survival at the end of one year was 70%, and at the end
of two years 20%. There were no survivors at the end of three years. 
Conclusion: ORMS in Karachi is a disease with a dismal survival. It may reflect a late presentation, or shorter
adult ORMS survival or a manifestation of a different genetic pattern, associated with rapid evolution and poor
prognosis. Health education for the population, especially parents and health providers is essential for early
ORMS diagnosis. Pediatricians, ophthalmologists and health professionals, can play a vital role. Healthcare
planning should focus on capacity building for ophthalmologic screening. Cytogenetic studies are advised to
determine the genetic pattern (JPMA 54:561;2004).
Introduction
Rhabdomyosarcoma (RMS) is composed of cells
with histopathological features of striated muscle in various
stages of embryogenesis. Ocular RMS (ORMS) is the
occurrence of this tumor in the area of the eye, mostly ocu-
lar soft tissues but rarely the orbit or ocular adnexal struc-
tures and even within the eye. RMS is the most common
primary malignancy of the orbit in children; the most com-
mon intraocular malignant lesion being retinoblastoma.
Primarily a childhood tumor, the average age at presentation
is 4-7 years.1-3 RMS has also been observed in adults.4-9
Derived from primitive undifferentiated mesenchy-
mal cells, RMS can be divided into 4 major histologic cate-
gories: embryonal, alveolar, botryoid embryonal, and pleo-
morphic. Embryonal RMS (ERMS) is the most common
subtype observed in children, accounting for 40-60% of all
RMS cases in this age group.10,11 These tumors are most
commonly observed either in the genitourinary region or the
head and neck region.
Histologically, they have high cytologic variability,
representing several stages of skeletal muscle morphogene-
sis. Desmin and muscle specific actin are immunochemical
stains used for identifying RMS, though these stain smooth
muscle as well. Myogenin and MyoD1 are more specific for
skeletal muscle.11 Ultrastructural studies are largely of aca-
demic interests and for confirmation of RMS if facilities are
available. At present three methods of RMS staging or its
modifications are in use, group staging, TNM and Risk clas-
sification. (Tables 1-2).12-14 Embryonal RMS (ERMS) cells
show a loss of specific genome material from the short arm of
chromosome 11 (11p15), suggesting the presence  of a  tumor
suppressor gene.  Another  molecular
feature characteristic of embryonal RMS is its lack of gene
amplification. The cellular DNA content of embryonal
RMS is  hyperdiploid.15-18 
RMS clinically presents with ptosis (droopy eyelid),
and/or unilateral proptosis (eye prominence), as a sub-con-
junctival tumor, dislocation of the lens, or impairment of
ocular mobility. It is usually found in the superonasal orbit
(that is under the upper lid near the nose). Due to its vari-
able manifestations it may imitate orbitocellulitis, chalazae,
epibulbar papilloma or as naso lacrimal duct obstruc-
tion.11,19,20 Rapid evolution, tumour burden (tumour size
>5.cms.) and regional lymph node involvement are indica-
tors of poor prognosis. Computed axial tomography (CT-
scan) and magnetic resonance imaging (MRI) typically
show a mass adjacent to or attached to one of the ocular or
orbital muscles. CT is particularly helpful because it shows
orbital bone tumor invasion and characteristic focal calcifi-
cation. Magnetic resonance (MR) imaging allows this tumor
to be differentiated from pseudogliomas, such as Coats dis-
ease and retrolental fibroplasia. CT and MR imaging help in
the differentiation from dermoid, cavernous hemangioma,
and lymphangioma.21
Early diagnosis, complete surgical resection fol-
lowed by a combination of chemotherapy and irradiation
offer approximately 70 to 90% 3-year survival. RMS is con-
sidered controlled if there is no recurrence after 3 years.22-24
The objective was to study the epidemiology of ORMS and
identify it as a malignancy with a good prognosis if diag-
nosed and treated early.
Methods
Incident RMS cases recorded at the Karachi Cancer
Registry during 1st January 1998 to 31st December 2002
were reviewed. The data were classified using ICD-O2
(International Classification of Diseases-Oncology, 2nd edi-
tion) and computerized using a customized version of
Canreg-3, with internal checks on the validity of the entered
data.19 Manual and computerized validity checks for the
Table 1.  ORMS staging system.
Group staging system
Group I 13% localized disease complete surgical resection no regional nodal involvement. 
Group IIA 21% Grossly resected microscopic residual disease no regional involvement. 
Group IIB complete resection no residual disease regional nodal involvement.
Group IIC microscopic residual disease regional nodal involvement.
Group III 48% incomplete resection gross residual disease. 
Group IV 18% Distant metastasis 
TNM staging system
Stage I Disease is localized and involves the orbit, the head and neck region
Stage II Localized disease of any unfavorable primary site not included in the The primary tumor must be <  or = 5 cm  in
stage I category. diameter.
Stage III Localized disease of any unfavorable primary site not included in the Primary tumor is > 5 cm in diameter and/or
stage I category. it involves regional lymph nodes.
Stage IV Metastatic disease at the time of diagnosis.
Risk classification  
Low risk (1) occurring at a favorable site (stage I) 
(Embryonal RMS) (2) occurring at an unfavorable site with complete resection (group I),
(3) occurring at an unfavorable site with microscopic residual 
disease (group II) 
Intermediate risk (1) embryonal RMS occurring at an unfavorable site with gross residual 
disease (group III)
(2) metastatic embryonal RMS and are younger than 10 years 
(3) any nonmetastatic alveolar RMS at any site 
High risk Metastatic disease unless younger than 10 years and have embryonal metastasis
cancer data were performed as per recommendations
of International Agency for Research on Cancer (IARC)
and International Association of Cancer Registries
(IACR).25-27 This involved factors influencing comparabili-
ty i.e., classification and coding. For precision only cases
diagnosed microscopically were included in the study. The
residency status of cases was re-ascertained and rechecked.
People residing in the specified geographical regions for
more than six months were considered residents.
Demographical variables recorded were the hospital
patient-number, date of incidence, name, age, sex, address,
ethnicity, topography, morphology, grading and staging.
Tumors were categorized according to the UICC, TNM
staging system, to standardize with the staging systems in
other parts of the world.12
Incidence rates were calculated based on the 1998
census (copy obtained from the Sindh Bureau of Statistics),
assuming an annual growth rate of 3.5%.28 The growth rate
was based on the inter-census growth-rate and measures for
inflow and outflow of population, calculated by the Federal
Bureau of Statistics. Standardized incidence rate was calcu-
lated with an external reference population, the 'world' pop-
ulation with a given 'standard' age distribution.29 The
methodology applied was direct standardization, using 5-
year age groups. The rates given are the annual incidence
per 100,000 population, averaged over the number of years
for which data are presented. The data were analyzed using
SPSS 10.0.
Results
Eighteen cases of RMS were reported to the Karachi
Cancer Registry during a five-year period, 1998-2002. Ten
cases were residents of Karachi Division (population of
9,802,134; males 5,261,712, females 4,540,422). RMS orig-
inated in the orbit in eight (80%) cases, conjunctiva in one
(10%) case and eyelid in one (10%) case. Nine cases present-
ed with proptosis, associated with conjunctivitis in four
cases. One case presented with eyelid swelling. Six cases
were observed in the right eye, whereas four were observed
in the left eye. The crude annual incidence rate was
0.13/100,000, the age standardized rate was 0.3/100,000.
The mean age of childhood cases was 10.4 years
Table 2. ORMS comparative studies.
Feng et al3 Takahashi et al2 Haik et al30 Shields et al22 Karachi
(n=10) (n=35) (n=18) (n=33) (n=10)
Orbit 9 - 4 25 8
Conjunctiva 1 - 14 4 1
Eyelid 2 - 1 1
Uveal tract - - 3
Proptosis - - - 10 5
Eyelid - - - 7 1
Blepharoptosis - - - 6 4
Initial diagnoses
Rhabdomyosarcoma - - - 8 10
Conjunctivitis - - - 5 -
Cellulitis - - - 5 -
Pseudotumor - - - 4 -
Mean age 4.2 5.2 6.0; 21.0 10.0 10.4; 24.8
Recurrence (total) - 43 15 10 2
Local - - - 6 2
Lymph node spread - 20 8 2 -
Distant metastasis - 23 7 2 -
Tumor-related death - - 7 1 10
(95% CI 4.0; 16.7); minimum 3 years, maximum 14
years, range, 11 years. The mean age of adult cases was 24.8
years (95% CI 12.8; 36.7); minimum 16 years, maximum 35
years, range, 19 years. At presentation, eight patients (80%)
were older than age 10 years and three patients (30%) were
older than 20 years. Only five cases (50%) could be catego-
rized as childhood malignancies (0-14 years). Two cases
presented at the age of 35 years, a male and a female. The
gender-ratio (M:F) was 2.3.
All ten cases were clinically diagnosed as RMS, and
histologically verified. Immunochemistry studies were pos-
itive for desmin, vimentin, and HHf35 actin and negative
for epithelial markers, (Cytokeratin CAM 5.2 and MNF)
and S100. Leucocyte Common Antigen (LCA), PAN B and
T, and retinoblastoma markers were also negative. Ultra
structural and cytogenetic studies were not conducted on
any histopathological specimen. Treatment included multi-
modality effort, which included surgical debulking and/or
enucleation, chemotherapy, and radiotherapy for all
patients. Tumors classified according TNM staging were a
stage III disease at presentation in eight (80%) cases and
stage I in two (20%) cases. The two Stage I, RMS were
adult cases, both presented with a recurrence within a year
of treatment. Survival at the end of one year was 70% and
at the end of two years 20%. There were no survivors at the
end of 3 years. 
Discussion
ORMS is an uncommon disease, the incidence rates
are not calculated, and therefore not a parameter of compar-
ison. There are few published articles, mostly single centre
studies, and a few registry reports consisting of 10-35 cases
or single case reports of adult ERMS.1-11 Predominantly a
childhood malignancy, it is rarely observed in adults.
Contrary to this in our series of ten cases, we observed an
equal distribution of adult and childhood orbital ERMS.  
Most studies report an early presentation and diag-
nosis, a mass or area of localized swelling usually marks
initial presentation. The mean age reported in different
series is 5.2 years by Takahashi et al2, 4.2 years by Feng et
al3, 6 years by Haik et al30, 7-8 years by Parham11 and 10
years by Sheild et al.22 Amongst children, a late presenta-
tion of ORMS was observed in Karachi, despite obvious
lesions associated with pain, in half the patients. The mean
age at diagnosis was 10.4 years, with two cases presenting
at 14 years of age. The mean age being reported, here is
therefore the highest documented and the plausible reason
could be a late diagnosis. Three out of the five childhood
cases presented with an erosion into the paranasal sinuses
and facial bones. 
Primary ERMS is extremely rare in adults. The old-
est documented age is 38 years; the highest age in our series
is 35 years. In the adult cases, presentation was earlier, with
a time lapse of 3-4 weeks before diagnosis. The presenting
complaints were conjunctivitis in four cases, and eyelid
swelling in one case.  
The cases were categorized by TNM (tumor, node,
metastasis) system which takes the size and location into
consideration. The other available options were 'Initial stag-
ing system', adopted by the first 3 intergroup RMS studies,
which group patients based on extent of disease and com-
pleteness of initial surgical resection. As we did not have
reliable information of the surgical process and residual dis-
ease this system could not be utilized. The TNM staging
does not take the extent of surgery into account, thus it was
more feasible for our system. The risk classifications, is
more appropriate for planning treatment options. 
The survival in Karachi is the lowest reported in lit-
erature. Shield et al22 reported a 70% 5-year survival with
gross disease following surgery (Risk group III); 90% 5-
year survival in patients without residual disease (Risk
group I) and an 80% 5-year survival with microscopic resid-
ual disease (Risk group II), when ORMS is seen in children
younger than 10 years of age. Takahashi2 et al reported a
52% 3-year survival in 1970's, and 86% in the 1980's in
childhood ORMS. Haik30 et al reported a 61% six-year sur-
vival. 
Cytogenetic studies were not conducted therefore
one remains in doubt if the late mean age of childhood
ORMS and the adult presentation are not a manifestation of
a different genetic pattern, more compatible with a rapid
evolution and poor prognosis.
Conclusion
ORMS in Karachi is a disease with a poor prognosis
and a dismal survival. Cytogenetic studies are advised to
determine the genetic pattern. Health education for the pop-
ulation, especially parents and health providers is essential
for early ORMS diagnosis. Pediatricians, ophthalmologists
and health professionals, can, play a vital role. Healthcare
planning should focus on capacity building for ophthalmo-
logic screening. 
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